National Institute of Biological Sciences, Zhongguancun Life Science Park, Beijing 102206, China; email:
Annu Rev Cell Dev Biol. 2015;31:125-47. doi: 10.1146/annurev-cellbio-100814-125241. Epub 2015 Oct 2.
Hepatitis B virus (HBV) infection affects 240 million people worldwide. A liver-specific bile acid transporter named the sodium taurocholate cotransporting polypeptide (NTCP) has been identified as the cellular receptor for HBV and its satellite, the hepatitis D virus (HDV). NTCP likely acts as a major determinant for the liver tropism and species specificity of HBV and HDV at the entry level. NTCP-mediated HBV entry interferes with bile acid transport in cell cultures and has been linked with alterations in bile acid and cholesterol metabolism in vivo. The human liver carcinoma cell line HepG2, complemented with NTCP, now provides a valuable platform for studying the basic biology of the viruses and developing treatments for HBV infection. This review summarizes critical findings regarding NTCP's role as a viral receptor for HBV and HDV and discusses important questions that remain unanswered.
乙型肝炎病毒 (HBV) 感染影响全球 2.4 亿人。一种名为钠牛磺胆酸共转运多肽 (NTCP) 的肝脏特异性胆酸转运蛋白已被确定为 HBV 及其卫星病毒丁型肝炎病毒 (HDV) 的细胞受体。NTCP 可能是 HBV 和 HDV 在进入水平上肝脏嗜性和种属特异性的主要决定因素。NTCP 介导的 HBV 进入会干扰细胞培养物中的胆酸转运,并与体内胆酸和胆固醇代谢的改变有关。用 NTCP 补充的人肝癌细胞系 HepG2 现在为研究病毒的基本生物学和开发 HBV 感染治疗方法提供了一个有价值的平台。本综述总结了关于 NTCP 作为 HBV 和 HDV 病毒受体的作用的关键发现,并讨论了仍未解答的重要问题。